Invitae (NVTAQ)
(Delayed Data from OTC)
$0.01 USD
+0.01 (900.00%)
Updated Jun 28, 2024 03:59 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVTAQ 0.01 +0.01(900.00%)
Will NVTAQ be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NVTAQ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVTAQ
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates
NVTAQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
Other News for NVTAQ
Invitaeās April 2024 Bankruptcy Report Warns Investors
New Research Demonstrates the Importance of Genetic Testing for Many Cancers Not Currently Covered by Clinical Guidelines
Invitae Receives Court Approval for Sale to Labcorp
US Bankruptcy Court approves Invitae sale to Labcorp
Invitae Nears Asset Sale to Labcorp Amid Bankruptcy Process